- Clinical Trials
Genprex is scheduled to join the U.S. broad-market Russell 3000 Index when FTSE Russell, a leading global index provider, reconstitutes its 2020 indices after the markets close on Friday, June 26.
Mr. Varner will deliver an overview of the Company and provide updates on its product pipeline.
The exercised warrants include all warrants that have been issued to investors in the Company’s public financings to date and represent approximately 70% of the Company’s overall outstanding warrants.
New license agreement expands Genprex’s oncology franchise
Company provides updates on recent regulatory, clinical, operational, and business developments
Proven executive with clinical operations expertise to guide the Company’s clinical programs with gene therapies
These board additions will enhance the Company’s ability to execute on key corporate initiatives.
These seasoned industry professionals combined with the company’s newly strengthened balance sheet will drive key clinical programs.
Dr. George Gittes, the lead researcher and Harvard graduate that developed Genprex’s new potentially curative diabetes gene therapy, was featured in a video interview discussing the therapy.
Genprex will present at the third annual LD Micro Virtual Conference on Wednesday, March 4 at 1:40 p.m. EST. Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company’s presentation and will be answering questions from investors.